Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium
Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium
复制标题
DOI：
10.2217/pgs-2017-0035
复制
发表时间：
2017-07-01
期刊：
影响因子：
2.1
通讯作者：
Maitland-van der Zee, Anke H.
中科院分区：
文献类型：
--
作者：
Farzan, Niloufar;Vijverberg, Susanne J.;Maitland-van der Zee, Anke H.
目的：需要国际合作，以实现儿童哮喘的大规模药物基因组学研究。在这里，我们描述了儿童哮喘药物基因组学（PiCA）联盟的设计。材料和方法：参与PiCA的每项研究的研究者通过回答在线问卷提供了有关研究特征的数据。结果如下：PiCA联盟目前共招募了来自12个不同国家的21项研究，包括14，227名儿童/青少年（58%为男性）。56%的患者是白人。总共有7619人是吸入性皮质类固醇使用者。在13项研究中有哮喘急性发作数据的患者中，三分之一报告了尽管使用了吸入性皮质类固醇，但仍发生了急性发作。在联盟内未来的药物基因组学研究中，药物基因组学分析将在每个中心单独进行，并对结果进行荟萃分析。结论：PiCA是在多种族儿童哮喘人群中进行药物遗传学研究的有价值的平台。
Aim: International collaboration is needed to enable large-scale pharmacogenomics studies in childhood asthma. Here, we describe the design of the Pharmacogenomics in Childhood Asthma (PiCA) consortium. Materials & methods: Investigators of each study participating in PiCA provided data on the study characteristics by answering an online questionnaire. Results: A total of 21 studies, including 14,227 children/young persons (58% male), from 12 different countries are currently enrolled in the PiCA consortium. Fifty six percent of the patients are Caucasians. In total, 7619 were inhaled corticosteroid users. Among patients from 13 studies with available data on asthma exacerbations, a third reported exacerbations despite inhaled corticosteroid use. In the future pharmacogenomics studies within the consortium, the pharmacogenomics analyses will be performed separately in each center and the results will be meta-analyzed. Conclusion: PiCA is a valuable platform to perform pharmacogenetics studies within a multiethnic pediatric asthma population.